Although primary studies have reported the safety and efficacy of LITT as a primary treatment in glioma, they are limited by sample sizes and institutional variation in stereotactic parameters such as temperature and laser power. The current literature has yet to provide pooled statistics on outcomes solely for primary brain tumors according to the 2021 WHO Classification of Tumors of the Central Nervous System (WHO CNS5). In the present study, we identify recent articles on primary CNS neoplasms treated with LITT without prior intervention, focusing on relationships with molecular profile, PFS, and OS. This meta-analysis includes the extraction of data from primary sources across four databases using the Covidence systematic review manager. The pooled data suggest LITT may be a safe primary management option with tumor ablation rates of 94.8% and 84.6% in IDH-wildtype glioblastoma multiforme (GBM) and IDH-mutant astrocytoma, respectively. For IDH-wildtype GBM, the pooled PFS and OS were 5.0 and 9.0 months, respectively. Similar to rates reported in the prior literature, the neurologic and non-neurologic complication rates for IDH-wildtype GBM were 10.3% and 4.8%, respectively. The neurologic and non-neurologic complication rates were somewhat higher in the IDH-mutant astrocytoma cohort at 33% and 8.3%, likely due to a smaller cohort size.
尽管已有初步研究报告了激光间质热疗（LITT）作为胶质瘤主要治疗手段的安全性和有效性，但这些研究受限于样本量以及立体定向参数（如温度和激光功率）在不同机构间的差异。现有文献尚未根据2021年世界卫生组织中枢神经系统肿瘤分类标准（WHO CNS5），专门针对原发性脑肿瘤提供汇总的疗效统计数据。本研究筛选了近期关于未经前期干预、直接采用LITT治疗的原发性中枢神经系统肿瘤的文献，重点关注其与分子特征、无进展生存期（PFS）和总生存期（OS）的关联。通过Covidence系统评价管理工具从四大数据库中提取原始研究数据，进行荟萃分析。汇总数据显示，LITT可能是一种安全的初始治疗方案：在IDH野生型多形性胶质母细胞瘤（GBM）和IDH突变型星形细胞瘤中，肿瘤消融率分别达到94.8%和84.6%。对于IDH野生型GBM，汇总的PFS和OS分别为5.0个月和9.0个月。其神经系统与非神经系统并发症发生率分别为10.3%和4.8%，与既往文献报道水平相近。IDH突变型星形细胞瘤组的神经系统与非神经系统并发症发生率略高（分别为33%和8.3%），这可能与该队列样本量较小有关。
肿瘤(癌症)患者之家